PolyPeptide Group AG (PPGN.SW)

30.30 -0.10 (-0.33%) 收市：05:31PM CEST

PolyPeptide Group AG

Neuhofstrasse 24
Baar 6340
Switzerland
41 435 020 580
https://www.polypeptide.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 1,273

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Klaus Peter Wilden	Executive Chair	305.77k	無	1957
Mr. Juan Jose Gonzalez	Chief Executive Officer	1.17M	無	1972
Mr. Marc Augustin	Chief Financial Officer	無	無	1972
Mr. Jens Fricke	Director of Global Operations	無	無	1965
Rene Vestergaard	Director of Corporate Finance	無	無	無
Mr. Olivier Ludemann-Hombourger	Director Global Innovation & Technology	無	無	1972
Ms. Christina Del Vecchio	General Counsel & Corporate Secretary	無	無	1978
Mr. Neil James Thompson	Director of Global Sales & Marketing	無	無	1972
Ms. Monika Casanova	Chief Human Resources Officer	無	無	1979
Christophe Chevalier	Head of Technical Department - Braine	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CHF。

描述

PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

公司管治

截至 無 止，PolyPeptide Group AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。